Looking into Concert Pharmaceuticals's Return on Capital Employed

After pulling data from Benzinga Pro it seems like during Q2, Concert Pharmaceuticals CNCE earned $6.22 million, a 125.93% increase from the preceding quarter. Concert Pharmaceuticals also posted a total of $32.02 million in sales, a 640240.0% increase since Q1. Concert Pharmaceuticals collected $5.00 thousand in revenue during Q1, but reported earnings showed a $23.98 million loss.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Concert Pharmaceuticals posted an ROCE of 0.05%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Concert Pharmaceuticals's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Analyst Predictions

Concert Pharmaceuticals reported Q2 earnings per share at $0.16/share, which beat analyst predictions of $-0.74/share.